Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Andrew Paulson

Medical Oncology Dallas, TX Medical Doctor

NPI 1821257072 CMS profile 1183825

3410 Worth St, Dallas, TX 75246

Open in the dashboard

General payments

$66,889

73 records reported · program years 2019–2025

Research payments

$14,657

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$11,456,064 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Andrew Paulson of Dallas, TX is reported in the CMS Open Payments database as having received $66,889 across 73 general payments and $14,657 in research payments paid to them. Separately, studies naming them as principal investigator received $11,456,064 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 87th percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $15,664 12
2024 General $1,933 5
2023 General $18,771 29
2022 General $10,886 9
2021 General $6,753 6
2020 General $11,213 7
2019 General $1,668 5
2019 Research $14,657 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew Paulson
  • Medical Oncology median
  • Middle half of Medical Oncology
  • National median

In program year 2025, general payments to Andrew Paulson were reported at $15,664. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.

Show as a table
Year Andrew Paulson Medical Oncology median Middle half National median
2019 $1,668 $968 $140–$6,658 $163
2020 $11,213 $747 $102–$5,891 $114
2021 $6,753 $430 $50–$4,098 $132
2022 $10,886 $812 $127–$4,907 $149
2023 $18,771 $957 $144–$5,248 $160
2024 $1,933 $1,042 $149–$5,650 $164
2025 $15,664 $1,128 $147–$5,675 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. E.R. Squibb & Sons, L.L.C. $11,598 14 payments
  2. Exelixis Inc. $8,555 7 payments
  3. Jazz Pharmaceuticals Inc. $6,130 8 payments
  4. Advanced Accelerator Applications $4,621 4 payments
  5. Array BioPharma Inc. $4,402 4 payments
  6. Amgen Inc. $4,244 2 payments
  7. Incyte Corporation $3,970 2 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $3,010 1 payment
  9. Astellas Pharma US Inc $2,992 2 payments
  10. Ipsen Bioscience Inc $2,700 2 payments
  11. Other $14,667 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $50,252 26 payments
  2. Honoraria $6,720 2 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $5,745 5 payments
  4. Travel and Lodging $2,246 8 payments
  5. Food and Beverage $1,914 31 payments
  6. Education $12 1 payment
Products named General payments · program years 2019–2025
  1. ZANIDATAMAB $6,130 8 payments
  2. CABOMETYX Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) $4,700 3 payments
  3. LUTATHERA $4,590 2 payments
  4. BRAFTOVI $4,267 3 payments
  5. CABOMETYX Oncology $2,865 2 payments
  6. RYBREVANT $2,335 3 payments
  7. Tepmetko $1,625 1 payment
  8. OPDIVO $1,594 1 payment
  9. Vectibix $1,500 1 payment
  10. TUKYSA $1,438 1 payment
  11. Other $4,547 23 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. E.R. Squibb & Sons, L.L.C. $14,657 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

347

Median for Medical Oncology: 414

Drug cost

$746,280

Median for Medical Oncology: $849,427

Branded share of claims

39.5%

Median for Medical Oncology: 28.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tibsovo Ivosidenib Brand 13 $429,879
Xermelo Telotristat Etiprate Brand 26 $235,646
Creon Lipase/Protease/Amylase Brand 27 $55,910
Eliquis Apixaban Brand 20 $11,176
Octreotide Acetate Generic 16 $6,637
Imatinib Mesylate Generic 19 $2,209
Opium Tincture Generic 17 $1,184
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 39 $1,174
Fentanyl Generic 11 $637
Oxycodone Hcl Generic 15 $401

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,431 Part D prescribers listed as Medical Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 173 billing codes

Paid by Medicare

$1,847,898

Of which drugs: $1,626,110

Medicare patients

480

Average age 74

Services billed

87,628

263 women, 217 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Cancer 46%
Arthritis 42%
Chronic kidney disease 30%
Diabetes 29%
Ischemic heart disease 28%
Depression 22%
COPD 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, pembrolizumab, 1 mg J9271 Office 29 8,800 $394,904
Injection, lanreotide, 1 mg J1930 Office 19 5,760 $216,257
Injection, daratumumab, 10 mg and hyaluronidase-fihj J9144 Office 16 5,220 $204,065
Injection, nivolumab, 1 mg J9299 Office 11 3,440 $84,955
Injection, leucovorin calcium, per 50 mg J0640 Office 21 521 $1,838
Injection, fosaprepitant, 1 mg J1453 Office 53 10,650 $1,208
Injection, fluorouracil, 500 mg J9190 Office 23 342 $784
Injection, palonosetron hcl, 25 mcg J2469 Office 73 1,030 $729
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 61 5,779 $589
Injection, carboplatin, 50 mg J9045 Office 19 142 $397

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RYBREVANT
  • Janssen Scientific Affairs, LLC $155
$155 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

76 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Medical Oncology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record